EKF Diagnostics Holdings PLC
LSE:EKF
Intrinsic Value
EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. [ Read More ]
The intrinsic value of one
EKF
stock under the Base Case scenario is
25.96
GBX.
Compared to the current market price of 27.4 GBX,
EKF Diagnostics Holdings PLC
is
Overvalued by 5%.
EKF Diagnostics Holdings PLC's market capitalization is 124.3m GBX.
EKF stock price is 27.4 GBX.
EKF stock (25.96 GBX) is 5% less than its price (27.4 GBX).
EKF has upside potential of 16% compared to the average analyst price target.
Open Wall St Estimates
EKF's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 9%.
EKF's Revenue is forecast to grow at a rate of 8% per year over the next 3 years.
EKF's ROE (Return on Equity) for the past 12 months is very low and is equal to 3%.
EKF has positive Net Income for the last twelve months.
EKF has positive Operating Income for the last twelve months.
EKF's ROIC (Return on Invested Capital) has decreased in the last 3 years from 17% to 9%.
EKF has positive three-year average ROIC (Return on Invested Capital): 15%. The company is efficient at using invested capital to generate operating income.
EKF has negative Free Cash Flow for the last twelve months.
EKF's Revenue has been falling by 7% per year for the last 3 years.
EKF's ROE (Return on Equity) has significantly decreased in the last 3 years from 15% to 3%.
EKF has positive three-year average ROE (Return on Equity): 5%. The company is efficient at transforming stockholders' equity into net income.
EKF's Revenue has dropped by 21% over the past 12 months.
EKF has positive Gross Profit for the last twelve months.
EKF's short-term assets (26m GBP) exceed its short-term liabilties (9m GBP).
EKF's D/E (Debt to Equity) is very low and is equal to 0.01.
EKF's long-term assets (81m GBP) exceed its long-term liabilties (14m GBP).
EKF has negative Net Debt. This means that the company has more cash and short-term investments (8m GBP) than debt (618k GBP).
EKF's Altman Z-Score is very high and is equal to 8.1.
EKF earns more than enough operating income (5m GBP) to safely cover interest payments on its debt (47k GBP).
Valuation Backtest
EKF Diagnostics Holdings PLC
Run backtest to discover the historical profit from buying and selling
EKF
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
EKF Diagnostics Holdings PLC
Balance Sheet Decomposition
EKF Diagnostics Holdings PLC
| Current Assets | 25.6m |
| Cash & Short-Term Investments | 7.7m |
| Receivables | 9.1m |
| Other Current Assets | 8.8m |
| Non-Current Assets | 55.3m |
| Long-Term Investments | 276k |
| PP&E | 24.8m |
| Intangibles | 30.2m |
| Other Non-Current Assets | 18k |
| Current Liabilities | 9.5m |
| Accounts Payable | 5.5m |
| Other Current Liabilities | 4m |
| Non-Current Liabilities | 4.2m |
| Long-Term Debt | 618k |
| Other Non-Current Liabilities | 3.6m |
Earnings Waterfall
EKF Diagnostics Holdings PLC
|
Revenue
|
52.6m
GBP
|
|
Cost of Revenue
|
-28.2m
GBP
|
|
Gross Profit
|
24.4m
GBP
|
|
Operating Expenses
|
-19.5m
GBP
|
|
Operating Income
|
4.9m
GBP
|
|
Other Expenses
|
-2.6m
GBP
|
|
Net Income
|
2.4m
GBP
|
Free Cash Flow Analysis
EKF Diagnostics Holdings PLC
What is Free Cash Flow?
EKF Profitability Score
Profitability Due Diligence
EKF Diagnostics Holdings PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
EKF Diagnostics Holdings PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
EKF Solvency Score
Solvency Due Diligence
EKF Diagnostics Holdings PLC's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Score
EKF Diagnostics Holdings PLC's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EKF Price Targets Summary
EKF Diagnostics Holdings PLC
According to Wall Street analysts, the average 1-year price target for
EKF
is 31.88 GBX
with a low forecast of 25.25 GBX and a high forecast of 37.8 GBX.
Shareholder Return
EKF Price
EKF Diagnostics Holdings PLC
| Average Annual Return | 20.46% |
| Standard Deviation of Annual Returns | 58.1% |
| Max Drawdown | -72% |
| Market Capitalization | 124.3m GBX |
| Shares Outstanding | 454 493 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
EKF Diagnostics Holdings PLC
Country
Industry
Market Cap
Dividend Yield
Description
EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. The company operates in Germany, the United States, Russia and the United Kingdom.
Contact
IPO
Employees
Officers
The intrinsic value of one
EKF
stock under the Base Case scenario is
25.96
GBX.
Compared to the current market price of 27.4 GBX,
EKF Diagnostics Holdings PLC
is
Overvalued by 5%.
You don't have any saved screeners yet
